insights_auto
Why is 4547 up 3.20%?
Dive Deeperchevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥3,865.00
arrow_upward
+3.20%(+120.00) 1D
Oct 1, 2:48:09 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
Â¥3,720
High
Â¥3,870
Low
Â¥3,715
Mkt. cap
179.65B
Avg. vol.
64.84K
Volume
71.60K
Dividend
3.10%
Quarterly dividend
Â¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
11.46
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥337
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥3,720
High
Â¥3,870
Low
Â¥3,715
Mkt. cap
179.65B
Avg. vol.
64.84K
Volume
71.60K
Dividend
3.10%
Quarterly dividend
Â¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
11.46
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥337
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
Benzinga
·
27 minutes ago
Stock Market: Will S&P 500 Open Up or Down Today?
TradingView
·
9 hours ago
Q3 Earnings on Track for 8th Consecutive Quarter of Double-Digit Growth
FXStreet
·
6 hours ago
Dow Jones Industrial Average fades a soft-inflation bounce as yields climb
FOREX.com
·
3 hours ago
S&P 500 Forecast: SPX Continues to Drift Away from Record Highs
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorPharmaceutical industry
Websitekissei.co.jp